The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients

(2019) John R. Jones et al.   HAEMATOLOGICA

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

(2018) Brian A. Walker et al.   BLOOD

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma

(2018) Leo Rasche et al.   BLOOD

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

(2018) Marjorie Pick et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma

(2018) Faith E. Davies et al.   HAEMATOLOGICA

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

(2018) Brian A. Walker et al.   LEUKEMIA

Spectrum and functional validation of PSMB5 mutations in multiple myeloma

(2018) Santiago Barrio et al.   LEUKEMIA

MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment

(2018) Ola Landgren et al.   SEMINARS IN HEMATOLOGY

Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic

(2018) Gareth J. Morgan et al.   Expert Review of Hematology

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma

(2018) Faith E. Davies et al.   HAEMATOLOGICA

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

(2018) Aurore Perrot et al.   BLOOD

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

(2018) Molly Went et al.   Nature Communications

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

(2018) Vallari Shah et al.   BLOOD

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma

(2018) L. Rasche et al.   LEUKEMIA

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

(2017) Carolina Schinke et al.   HAEMATOLOGICA

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

(2017) Sharmilan Thanendrarajan et al.   HAEMATOLOGICA

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

(2017) Philippe Moreau et al.   JOURNAL OF CLINICAL ONCOLOGY

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

(2017) L. Rasche et al.   Nature Communications

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates

(2017) Olena Kis et al.   Nature Communications

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

(2017) S S Chavan et al.   Blood Cancer Journal

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma

(2017) Caleb K. Stein et al.   Oncotarget

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

(2017) Yuji Mishima et al.   Cell Reports

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

(2017) Carolina Schinke et al.   HAEMATOLOGICA

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

(2017) Sharmilan Thanendrarajan et al.   HAEMATOLOGICA

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features

(2016) Leo Rasche et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

(2016) N. Weinhold et al.   BLOOD

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

(2016) K. M. Kortum et al.   BLOOD

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

(2016) M. S. Raab et al.   BLOOD

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

(2016) Yogesh S. Jethava et al.   CLINICAL CANCER RESEARCH

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

(2016) S Mithraprabhu et al.   LEUKEMIA

Proteomic profiling in plasma cell disorders: a feasibility study

(2016) Sham Mailankody et al.   LEUKEMIA & LYMPHOMA

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution

(2016) J. G. Lohr et al.   Science Translational Medicine

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

(2016) K M Kortuem et al.   Blood Cancer Journal

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

(2016) Y Jethava et al.   Blood Cancer Journal

Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P)

(2015) K. M. Kortüm et al.   ANNALS OF HEMATOLOGY

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

(2015) Tobias Meißner et al.   BMC Medical Genomics

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation

(2015) Mathew Weinstock et al.   BRITISH JOURNAL OF HAEMATOLOGY

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibiting MEK in MAPK pathway-activated myeloma

(2015) C J Heuck et al.   LEUKEMIA

Clinical value of molecular subtyping multiple myeloma using gene expression profiling

(2015) N Weinhold et al.   LEUKEMIA

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

(2015) L Vincent et al.   Blood Cancer Journal

Curing myeloma at last: defining criteria and providing the evidence

(2014) B. Barlogie et al.   BLOOD

Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma

(2014) J.P. Sharman et al.   Clinical Lymphoma Myeloma & Leukemia

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

(2014) L Melchor et al.   LEUKEMIA

One cell at a time

(2014) Edward J. Fox et al.   NATURE

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

(2013) S. Z. Usmani et al.   BLOOD

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

(2013) Joseph R. Mikhael et al.   MAYO CLINIC PROCEEDINGS

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

(2013) Niels Weinhold et al.   NATURE GENETICS

Targeting the BRAF V600E Mutation in Multiple Myeloma

(2013) M. Andrulis et al.   Cancer Discovery

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases

(2012) Leo Rasche et al.   ANNALS OF HEMATOLOGY

Darwinian evolution and tiding clones in multiple myeloma

(2012) N. J. Bahlis   BLOOD

How I treat plasma cell leukemia

(2012) N. W. C. J. van de Donk et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

(2012) S. Z. Usmani et al.   HAEMATOLOGICA

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

(2012) S. Waheed et al.   HAEMATOLOGICA

The prognostic significance of cytogenetics and molecular profiling in multiple myeloma

(2011) Jeffrey R. Sawyer   Cancer Genetics

Multiple Myeloma

(2010) Jacob Laubach et al.   Annual Review of Medicine

Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients

(2010) Lene Meldgaard Knudsen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

(2009) T. B. Bartel et al.   BLOOD

Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome

(2008) M C Minnema et al.   BONE MARROW TRANSPLANTATION